8-K 1 r8k-122004.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 20, 2004 HEMISPHERX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 0-27072 52-0845822 (state or other juris- (Commission (I.R.S. Employer diction of incorporation) File Number) (Identification No.) 1617 JFK Boulevard, Philadelphia, Pennsylvania 19103 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (215) 988-0080 (Former name or former address, if changed since last report) ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE As agreed with the Company at the outset of becoming a director, having served for a period of 1 year, Dr. Antoni Esteve has resigned as a director. Dr. Esteve will continue to meet with top management of the Company on an ongoing basis with regard to its developmental drug Ampligen, with particular focus on the HIV/HCV clinical trial using Ampligen being conducted in Spain by Laboratorios del Dr. Esteve, S.A. in collaboration with the Company. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEMISPHERX BIOPHARMA, INC. December 20, 2004 By: /s/William A. Carter ---------------------------- William A. Carter, M.D., President